Regeneron drops as Q1 beat is overshadowed by margin headwinds from manufacturing issue
Regeneron shares fell after first-quarter 2026 results highlighted a near-term gross-margin hit tied to a manufacturing disruption, despite revenue growth. Management said production has resumed in Q2 and expects margins to normalize by the end of Q2.
1. What’s moving the stock
Regeneron Pharmaceuticals (REGN) is trading lower after reporting first-quarter 2026 results that beat on revenue and earnings metrics but flagged near-term profitability pressure. The key overhang is a gross-margin headwind linked to a manufacturing disruption, which investors appear to be weighing more heavily than the top-line beat.
2. The key detail investors are reacting to
Regeneron indicated that production resumed in the second quarter and that it expects gross margins to normalize by the end of Q2, implying the impact is concentrated in the near term rather than structural. Still, the acknowledgement of a manufacturing-related margin hit and related guidance dynamics is pressuring the stock today.
3. The numbers in focus
Regeneron posted first-quarter 2026 total revenue of $3.605 billion, up 19% year over year, with GAAP diluted EPS of $6.75 and non-GAAP diluted EPS of $9.47. The market reaction suggests the margin outlook and execution risk around manufacturing and product supply are the central issues for the session.